XBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $7.19

XBiotech Inc. (NASDAQ:XBIT)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $7.19 and traded as high as $9.19. XBiotech shares last traded at $8.11, with a volume of 81,922 shares.

Analyst Ratings Changes

Separately, StockNews.com began coverage on XBiotech in a research note on Thursday, February 15th. They issued a “sell” rating on the stock.

XBiotech Trading Down 9.5 %

The firm has a market cap of $246.95 million, a P/E ratio of -9.89 and a beta of 1.45. The firm has a 50-day simple moving average of $7.19 and a 200-day simple moving average of $5.23.

XBiotech (NASDAQ:XBIT) last announced its earnings results on Friday, March 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter.

Institutional Trading of XBiotech

A number of institutional investors have recently made changes to their positions in XBIT. Swiss National Bank boosted its position in shares of XBiotech by 8.8% in the 1st quarter. Swiss National Bank now owns 46,800 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 3,800 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of XBiotech by 72.8% in the 1st quarter. JPMorgan Chase & Co. now owns 15,093 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 6,360 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of XBiotech by 32.0% in the 1st quarter. Bank of New York Mellon Corp now owns 78,874 shares of the biopharmaceutical company’s stock worth $681,000 after purchasing an additional 19,140 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of XBiotech by 50.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 153,918 shares of the biopharmaceutical company’s stock worth $1,330,000 after purchasing an additional 51,872 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in XBiotech by 15.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 44,693 shares of the biopharmaceutical company’s stock worth $387,000 after acquiring an additional 6,085 shares during the period. Institutional investors and hedge funds own 55.70% of the company’s stock.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.